International Registry to Collect Clinical and Treatment Data for Monogenic and Polygenic Autoinflammatory Diseases
Led by University of Siena · Updated on 2025-07-10
3500
Participants Needed
112
Research Sites
208 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration.
The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years.
Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.
CONDITIONS
Brief Title
AutoInflammatory Disease Alliance Registry (AIDA)
Research Team
L
Luca Cantarini, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with a monogenic autoinflammatory disease based on clinical features and confirmative genetic testing
Diagnosed with familial Mediterranean fever, Behçet's disease, Still disease, PFAPA syndrome, Schnitzler's disease, or chronic recurrent multifocal osteomyelitis according to established criteria
Diagnosed with undifferentiated systemic autoinflammatory disease
Diagnosed with non-infectious uveitis following standard nomenclature criteria
Diagnosed with anterior or posterior non-infectious scleritis
Diagnosed with spondyloarthritis according to ASAS and/or New York criteria
Diagnosed with Castleman disease
You will not qualify if you...
Informed consent or assent not provided by the patient or their legal representative
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person or remote)
Long-term Monitoring
Duration - Up to 10 years
Participants diagnosed with autoinflammatory diseases are observed over time with data collected during routine clinical visits.
Routine visits every 3 to 6 months
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Phase II Study Evaluating Subcutaneous GenSci048 Versus Placebo in Adults With Active Non-infectious Uveitis
Observational Study of Uveitis in Children Under 18 Years
Observational Study of YUTIQ 0.18 mg Implant for Treating Chronic Non-infectious Uveitis in Adults Aged 18 to 70
Observational Study of Canakinumab Treatment in Patients with Familial Mediterranean Fever and Stills Disease Including SJIA and Adult-Onset Stills Disease
Observational Study of Canakinumab Ilaris for Treating Schnitzlers Syndrome
Including Patients Starting Treatment for the First Time
Study of Pacritinib to Evaluate Safety and Effectiveness in Adults With VEXAS Syndrome
Randomized, Double-blind, Placebo-controlled Phase 2 Trial with Open-label Extension
Study of Adults and Children with Stills Disease to Understand Its Causes and Improve Care
Observational Italian Study on Siltuximab for Adults with Relapsed or Refractory Castleman Disease in Real-Life Treatment
Study of Using Optical Coherence Tomography to Analyze Inflammation in the Front Chamber of Eyes with Uveitis
International Registry to Collect Clinical and Treatment Data for Monogenic and Polygenic Autoinflammatory Diseases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.